mupirocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
aminoacyl-tRNA synthetase inhibitors 1857 12650-69-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mupirocin
  • mupricin
  • pseudomonic acid
  • turixin
  • mupirocin calcium
  • bactroban
  • BRL 4910A
A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.
  • Molecular weight: 500.63
  • Formula: C26H44O9
  • CLOGP: 1.54
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 4
  • TPSA: 146.05
  • ALOGS: -4.28
  • ROTB: 17

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1987 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 909.74 15.61 289 11937 24087 63452709
Chronic sinusitis 214.87 15.61 84 12142 12759 63464037
Paraesthesia oral 157.46 15.61 76 12150 19180 63457616
Procedural pain 152.20 15.61 77 12149 21492 63455304
Vaginal flatulence 102.06 15.61 34 12192 3259 63473537
Dyspepsia 89.11 15.61 104 12122 102092 63374704
Therapeutic product effect incomplete 87.65 15.61 114 12112 124942 63351854
Drug ineffective 85.63 15.61 411 11815 1044354 62432442
Proctitis 85.40 15.61 34 12192 5407 63471389
Female genital tract fistula 74.63 15.61 34 12192 7525 63469271
Radiculopathy 73.44 15.61 35 12191 8576 63468220
Vaginal discharge 71.25 15.61 35 12191 9163 63467633
Weight decreased 62.04 15.61 153 12073 276645 63200151
Colitis ulcerative 58.75 15.61 45 12181 26046 63450750
Colitis 55.51 15.61 57 12169 48471 63428325
Oral candidiasis 50.62 15.61 39 12187 22759 63454037
Frequent bowel movements 43.87 15.61 36 12190 22986 63453810
Hyperchlorhydria 41.52 15.61 15 12211 1829 63474967
Folate deficiency 37.22 15.61 15 12211 2460 63474336
Nasal vestibulitis 36.54 15.61 6 12220 20 63476776
Toxicity to various agents 36.40 15.61 3 12223 247247 63229549
Staphylococcal infection 32.64 15.61 40 12186 41216 63435580
Pyrexia 32.45 15.61 177 12049 470301 63006495
Purpura senile 30.88 15.61 9 12217 554 63476242
Tarsal tunnel syndrome 26.37 15.61 8 12218 566 63476230
Malaise 25.69 15.61 152 12074 415802 63060994
Erythema 25.40 15.61 83 12143 175668 63301128
Drug intolerance 25.28 15.61 14 12212 308647 63168149
Dermatitis atopic 24.62 15.61 18 12208 9706 63467090
Odynophagia 23.96 15.61 16 12210 7470 63469326
General physical health deterioration 23.59 15.61 5 12221 201397 63275399
Product dose omission issue 23.25 15.61 98 12128 234215 63242581
Rectal haemorrhage 23.01 15.61 37 12189 48993 63427803
Systemic lupus erythematosus 22.86 15.61 6 12220 208912 63267884
Humidity intolerance 20.80 15.61 6 12220 356 63476440
Sinusitis 20.34 15.61 92 12134 226561 63250235
Therapeutic product effect decreased 20.29 15.61 6 12220 193181 63283615
Resorption bone increased 20.12 15.61 8 12218 1266 63475530
Nausea 19.42 15.61 250 11976 854221 62622575
Vestibular disorder 19.23 15.61 8 12218 1423 63475373
Hospitalisation 18.95 15.61 47 12179 85034 63391762
Haematochezia 18.11 15.61 35 12191 53509 63423287
Cellulitis 17.97 15.61 45 12181 81913 63394883
Therapy interrupted 17.33 15.61 26 12200 32429 63444367
Bronchial oedema 17.17 15.61 4 12222 101 63476695
Skin exfoliation 16.87 15.61 30 12196 43072 63433724
Dry skin 16.63 15.61 35 12191 56852 63419944
Maternal exposure during pregnancy 16.58 15.61 11 12215 220051 63256745
Skin infection 16.03 15.61 17 12209 14985 63461811
Dermatitis 16.00 15.61 18 12208 16940 63459856

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis atopic 67.17 17.80 27 5556 5320 34946028
Nasal vestibulitis 52.22 17.80 8 5575 19 34951329
Food aversion 39.91 17.80 10 5573 419 34950929
Product use in unapproved indication 38.53 17.80 68 5515 117431 34833917
Staphylococcal infection 31.25 17.80 32 5551 32728 34918620
Toxic epidermal necrolysis 29.96 17.80 26 5557 21620 34929728
Pruritus 27.36 17.80 66 5517 141915 34809433
Burkholderia test positive 27.25 17.80 9 5574 1014 34950334
Pain of skin 26.98 17.80 15 5568 6094 34945254
Skin fissures 26.25 17.80 14 5569 5245 34946103
Cheilitis 23.04 17.80 10 5573 2381 34948967
Dry skin 21.92 17.80 26 5557 31261 34920087
Skin exfoliation 21.23 17.80 24 5559 27408 34923940
Skin discolouration 19.92 17.80 19 5564 17826 34933522
Cellulitis 19.09 17.80 32 5551 52919 34898429
Product dose omission issue 18.25 17.80 51 5532 119660 34831688

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 201.03 14.32 76 14356 11220 79718736
Chronic sinusitis 201 14.32 79 14353 12947 79717009
Procedural pain 160.56 14.32 80 14352 23004 79706952
Paraesthesia oral 151.46 14.32 74 14358 20397 79709559
Vaginal flatulence 108.08 14.32 33 14399 2542 79727414
Dyspepsia 85.79 14.32 102 14330 108585 79621371
Proctitis 81.93 14.32 34 14398 6398 79723558
Female genital tract fistula 80.92 14.32 33 14399 5942 79724014
Vaginal discharge 77.06 14.32 34 14398 7429 79722527
Radiculopathy 74.69 14.32 35 14397 8789 79721167
Therapeutic product effect incomplete 74.64 14.32 109 14323 141536 79588420
Weight decreased 63.97 14.32 174 14258 355024 79374932
Dermatitis atopic 55.92 14.32 30 14402 10026 79719930
Colitis ulcerative 51.89 14.32 46 14386 34696 79695260
Oral candidiasis 45.79 14.32 40 14392 29588 79700368
Colitis 45.41 14.32 61 14371 73246 79656710
Toxicity to various agents 42.24 14.32 12 14420 421528 79308428
Frequent bowel movements 39.96 14.32 37 14395 29502 79700454
Hyperchlorhydria 37.01 14.32 14 14418 2065 79727891
Folate deficiency 30.53 14.32 14 14418 3346 79726610
Food aversion 29.70 14.32 10 14422 1053 79728903
Cellulitis 27.63 14.32 61 14371 108999 79620957
Purpura senile 27.49 14.32 8 14424 522 79729434
Tarsal tunnel syndrome 27.40 14.32 8 14424 528 79729428
Product dose omission issue 26.84 14.32 102 14330 247435 79482521
Staphylococcal infection 23.89 14.32 40 14392 58255 79671701
Erythema 23.37 14.32 91 14341 223199 79506757
Resorption bone increased 22.93 14.32 9 14423 1466 79728490
Pyrexia 21.04 14.32 201 14231 678508 79051448
Odynophagia 21.02 14.32 17 14415 11310 79718646
Malaise 20.97 14.32 156 14276 489713 79240243
Dry skin 20.68 14.32 41 14391 67954 79662002
Drug interaction 20.59 14.32 27 14405 415156 79314800
Humidity intolerance 20.48 14.32 6 14426 401 79729555
Rectal haemorrhage 19.68 14.32 43 14389 76257 79653699
Skin exfoliation 18.94 14.32 35 14397 55065 79674891
Skin fissures 18.90 14.32 17 14415 13056 79716900
Skin cancer 18.73 14.32 18 14414 15022 79714934
Product use in unapproved indication 18.55 14.32 92 14340 250267 79479689
Knee operation 18.17 14.32 12 14420 5854 79724102
Drug intolerance 17.92 14.32 13 14419 264106 79465850
Bronchial oedema 17.86 14.32 4 14428 90 79729866
Skin infection 17.56 14.32 19 14413 18226 79711730
Nausea 17.45 14.32 256 14176 956940 78773016
Infusion related reaction 17.33 14.32 85 14347 230152 79499804
Pain of skin 17.28 14.32 17 14415 14596 79715360
Dermatitis contact 17.25 14.32 15 14417 11018 79718938
Steroid withdrawal syndrome 17.10 14.32 6 14426 715 79729241
Skin discolouration 16.60 14.32 28 14404 41006 79688950
Toxic epidermal necrolysis 16.19 14.32 29 14403 44552 79685404
General physical health deterioration 15.68 14.32 16 14416 275222 79454734
Vestibular disorder 15.57 14.32 8 14424 2447 79727509
Surgery 15.49 14.32 24 14408 32742 79697214
Pruritus 15.37 14.32 123 14309 394525 79335431
Otitis externa fungal 14.54 14.32 3 14429 45 79729911

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D06AX09 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
ANTIBIOTICS FOR TOPICAL USE
Other antibiotics for topical use
ATC R01AX06 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Other nasal preparations
FDA EPC N0000175515 RNA Synthetase Inhibitor Antibacterial
FDA MoA N0000175516 RNA Synthetase Inhibitors
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:48001 protein synthesis inhibitors
CHEBI has role CHEBI:35441 antiinfective agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Impetigo indication 48277006 DOID:8504
Staph Aureus Traumatic Skin Lesion Infection indication
Methicillin-Resistant Staphylococcus Aureus Nasal Colonization indication
Traumatic Skin Lesion Streptococcus Pyogenes Infection indication
Folliculitis off-label use 13600006 DOID:4409
Atopic dermatitis off-label use 24079001 DOID:3310
Eczema off-label use 43116000
Epidermolysis bullosa off-label use 61003004 DOID:2730
Ecthyma off-label use 85791004
Furunculosis off-label use 112650006
Minor Bacterial Skin Infections off-label use
Skin irritation contraindication 367466007




🐶 Veterinary Drug Use

SpeciesUseRelation
Dogs Bacterial infections of the skin caused by strains of Staphylococcus aureus Indication
Dogs Bacterial infections of the skin caused by Staphylococcus intermedius Indication

🐶 Veterinary products

ProductApplicantIngredients
Bactoderm Ointment Zoetis Inc. 1
Muricin Fougera Pharmaceuticals Inc. 1
Mupirocin Ointment USP, 2% Taro Pharmaceuticals U.S.A. Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.76 acidic
pKa2 12.42 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Isoleucine--tRNA ligase, cytoplasmic Enzyme IC50 9.10 CHEMBL
Isoleucine--tRNA ligase Enzyme INHIBITOR DRUGBANK CHEMBL
Isoleucine--tRNA ligase Enzyme INHIBITOR CHEMBL CHEMBL
Isoleucine--tRNA ligase Enzyme Ki 8.60 CHEMBL
Isoleucine--tRNA ligase Enzyme Ki 7.22 CHEMBL
Isoleucine--tRNA ligase, putative, EC 6.1.1.5 Unclassified IC50 7.24 IUPHAR

External reference:

IDSource
4019345 VUID
N0000147519 NUI
D01076 KEGG_DRUG
115074-43-6 SECONDARY_CAS_RN
4019345 VANDF
4021018 VANDF
C0085259 UMLSCUI
CHEBI:7025 CHEBI
MRC PDB_CHEM_ID
CHEMBL3989715 ChEMBL_ID
CHEMBL2068726 ChEMBL_ID
CHEMBL719 ChEMBL_ID
D016712 MESH_DESCRIPTOR_UI
DB00410 DRUGBANK_ID
10916 IUPHAR_LIGAND_ID
5276 INN_ID
D0GX863OA5 UNII
446596 PUBCHEM_CID
221128 RXNORM
198973 MMSL
47751 MMSL
5138 MMSL
5139 MMSL
720 MMSL
002802 NDDF
005869 NDDF
387397004 SNOMEDCT_US
441528009 SNOMEDCT_US
71453003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1010 OINTMENT 20 mg TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1010 OINTMENT 20 mg TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0168-0352 OINTMENT 20 mg TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 0904-7284 OINTMENT 20 mg TOPICAL ANDA 25 sections
BACTROBAN HUMAN PRESCRIPTION DRUG LABEL 1 16590-028 CREAM 20 mg TOPICAL NDA 22 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-158 OINTMENT 20 mg TOPICAL ANDA 16 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 16714-055 CREAM 20 mg TOPICAL ANDA 28 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 17856-0112 OINTMENT 20 mg TOPICAL ANDA 20 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 21695-188 OINTMENT 20 mg TOPICAL ANDA 19 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 21922-029 CREAM 2 g TOPICAL ANDA 23 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 42254-137 OINTMENT 20 mg TOPICAL ANDA 19 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 42254-229 OINTMENT 20 mg TOPICAL ANDA 20 sections
CENTANY HUMAN PRESCRIPTION DRUG LABEL 1 43538-300 OINTMENT 20 mg TOPICAL NDA 26 sections
Centany AT HUMAN PRESCRIPTION DRUG LABEL 1 43538-310 OINTMENT 20 mg TOPICAL NDA 26 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 45802-018 CREAM 20 mg TOPICAL ANDA 25 sections
MUPIROCIN HUMAN PRESCRIPTION DRUG LABEL 1 45802-018 CREAM 20 mg TOPICAL ANDA 25 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 45802-112 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 45802-112 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 45865-722 OINTMENT 20 mg TOPICAL ANDA 20 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 49999-644 OINTMENT 20 mg TOPICAL ANDA 20 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 49999-644 OINTMENT 20 mg TOPICAL ANDA 20 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-1587 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-1587 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-4349 OINTMENT 20 mg TOPICAL ANDA 24 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50090-4397 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50268-568 OINTMENT 20 mg TOPICAL ANDA 25 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0025 OINTMENT 20 mg TOPICAL ANDA 23 sections
mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0112 OINTMENT 20 mg TOPICAL ANDA 24 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-0180 OINTMENT 20 mg TOPICAL ANDA 22 sections
Mupirocin HUMAN PRESCRIPTION DRUG LABEL 1 50436-1010 OINTMENT 20 mg TOPICAL ANDA 23 sections